A high-activity UK & EU sector, led by NHS ENGLAND, most recent listing 14 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
This contract opportunity involves establishing non-exclusive discount agreements for finished pharmaceuticals with various active ingredients or combinations of active ingredients under an 'Open-House Model' as per § 130a Abs. 8 SGB V. Suppliers can join or sign contracts at any time under the same
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the pharmaceutical substances Dolutegravir and Rilpivirine, classified under ATC J05AR21. This agreement will be effective from July 1, 2025, to June 30, 2027. The contract is part of a framework that allows
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Epoetin Zeta, as permitted under Section 130a, Paragraph 8 of the German Social Code (SGB V). The GWQ ServicePlus AG, acting on behalf of health insurance companies, is seeking to
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Cyanocobalamin (ATC B03BA01) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from July 1, 2025, to June 30, 2027, with an option to extend for an additional 12 months.
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical product Somatropin, classified under ATC code H01AC01. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into contracts at any time during this perio
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Denosumab, marketed as Xgeva, in accordance with German social law. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into agreements at any
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Axitinib (ATC: L01EK01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or
This publication is about entering into non-exclusive discount contracts according to § 130c Abs. 1 SGB V in conjunction with § 130a Abs. 8 SGB V for finished medicinal products containing the active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57) as part of an "open-house model". Under unif
The KKH (Kaufmännische Krankenkasse) aims to establish non-exclusive discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process allows all eligible and interested pharmaceutical companies
This announcement is not for the awarding of a public contract as defined by the Public Procurement Directive (2014/24/EU) or competition law. It aims to inform interested pharmaceutical companies broadly and is published in the Supplement to the Official Journal of the European Union. The term 'Ope
